Read More Pharma Industry News Gilead’s $21bn cancer gamble faces major blow as Trodelvy fails in key breast cancer trial Gilead’s Trodelvy failed to meet the main goal in a Phase 3 breast cancer trial, raising new questions about its oncology growth strategy. byPallavi MadhirajuNovember 8, 2025